Highlight on Pronidesivir (GS-441524): The First Approved Drug for the Treatment of Feline Infectious Peritonitis (FIP)
- 6 November 2026
- journal article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
Abstract
No abstract availableFunding Information
- Central Public-interest Scientific Institution Basal Research Fund (2026JB18)
This publication has 49 references indexed in Scilit:
- Identification and evaluation of Nordihydroguaiaretic acid (NDGA) as an active traditional Chinese medicine compound inhibiting the 3C-like protease of feline infectious peritonitis virusVeterinary Microbiology, 2025
- Strategies for combating FIPV infection: antiviral agents and vaccinesResearch in Veterinary Science, 2025
- Pharmacokinetics, Mass Balance, Safety, and Tolerability of Obeldesivir in Healthy ParticipantsClinical Pharmacology & Therapeutics, 2024
- A randomized trial to assess the acceleration of viral clearance by the combination Favipiravir/Ivermectin/Niclosamide in mild-to-moderate COVID-19 adult patients (FINCOV)Journal of Infection and Public Health, 2024
- Nucleoside analog GS‐441524: pharmacokinetics in different species, safety, and potential effectiveness against Covid‐19Pharmacology Research & Perspectives, 2022
- Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in MiceCell Reports, 2020
- The nucleoside analog GS-441524 strongly inhibits feline infectious peritonitis (FIP) virus in tissue culture and experimental cat infection studiesVeterinary Microbiology, 2018
- From SARS to MERS: 10 years of research on highly pathogenic human coronavirusesAntiviral Research, 2013
- Differentiation of feline coronavirus type I and II infections by virus neutralization testVeterinary Microbiology, 2007
- Prevalence of feline coronavirus types I and II in cats with histopathologically verified feline infectious peritonitisVeterinary Microbiology, 2004